TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a first-person report published by Being Patient on Oct. 6, 2026, patient advocate Ron Carr describes three health notifications that changed how he understood his risks. The available source details two: a genetic result showing two APOE4 copies and a coronary calcium scan showing significant artery plaque. The supplied report cuts off before describing the third notification, and Carr’s account does not establish that testing or lifestyle changes prevent Alzheimer’s.
Ron Carr, a retired local government executive and patient advocate, says two health notifications changed how he understood his Alzheimer’s and cardiovascular risks: a genetic test showing two copies of APOE4 and a coronary artery calcium scan showing significant plaque. In a first-person report published by Being Patient on Oct. 6, 2026, Carr describes moving from fear about inherited risk toward discussions with clinicians about prevention; the supplied report does not include the promised account of a third notification.
Carr writes that he received the APOE4 result about two years before the article’s publication. He describes initially treating ordinary memory lapses as possible signs of disease and trying successive diets, exercise routines and supplements. He says learning more about the distinction between a risk factor and a diagnosis helped him feel less helpless. The report does not say Carr has Alzheimer’s disease.
Carr’s second notification followed a coronary artery calcium scan arranged after discussions with his USC clinician. He says it showed significant calcified plaque, concentrated largely in his left anterior descending artery. At 65, he says, his clinician diagnosed atherosclerotic cardiovascular disease and changed the targets for his cholesterol-related treatment. Carr reports that follow-up testing found no evidence of structural heart damage.
These details are Carr’s personal account, not a clinical study or a report of outcomes for a wider group. He says the scan was prompted partly by his APOE4 status and changed his conversations about prevention. The source material provided for this article ends during his description of those conversations, before it explains the third notification or gives further details about subsequent care.
How Risk Led to a Heart Scan
Carr’s account illustrates how information about one kind of risk can prompt a closer look at another. He describes learning that APOE4 relates not only to Alzheimer’s risk but also to lipid transport, then undergoing a scan that identified coronary plaque despite feeling well. That sequence is his experience; it does not show that everyone with APOE4 should have the same test or treatment.
The practical point in the report is the role of clinical discussion. A genetic result can be emotionally difficult and does not predict with certainty what will happen to an individual. Carr says he came to see it as information to discuss and act on, rather than a diagnosis. His heart scan, by contrast, led to a cardiovascular diagnosis and changes to his care. Readers should not treat his account as individualized medical guidance; test decisions and risk management depend on a clinician’s assessment.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
As an affiliate, we earn on qualifying purchases.
From APOE4 Result to Scan
Carr identifies himself as a retired local government executive and patient advocate who focuses on Alzheimer’s prevention, genetic testing and cardiovascular health. He says he has shared his perspective through the USC Center for Personalized Brain Health and the Family Heart Foundation, where he serves as an ambassador. The Being Patient piece is written in the first person and centers on how he responded to personal health information.
After receiving his genetic result, Carr says he read research and repeatedly changed his diet and exercise habits. He also describes taking supplements and prescription sleeping pills, which left him groggy and irritable. He later says learning that APOE4 is a risk factor, not a diagnosis, changed his outlook. The article cites a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That population-level estimate is not a prediction of an individual’s risk or proof that a particular change will prevent dementia.
Carr also connects his concern about heart disease to his father, who had a heart attack at 65. Carr says he had run regularly, followed a heart-conscious diet and eventually took statins before the scan revealed plaque. The contrast he draws is between his father’s heart attack as the first indication of disease and his own scan result; it is personal context, not a comparison of treatment outcomes.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in his Being Patient report
The Third Notification Is Missing
The supplied source text stops partway through Carr’s description of conversations with people close to him. Although the title promises three notifications, the material available here describes only the APOE4 result and the coronary calcium scan. The third notification, its timing and what it showed are not established by the supplied text.
The excerpt also does not provide the scan’s numerical calcium score, detailed treatment regimen, or a full account of Carr’s subsequent health. It does not establish that APOE4 testing, calcium scanning, a particular diet or supplements prevent Alzheimer’s. Carr’s clinical decisions and outcomes should be understood as his account, not general recommendations.
Full Account and Clinical Follow-Up
The next step for readers seeking the complete story is to consult the full Being Patient report, which may contain the missing third notification and the rest of Carr’s account. The supplied material gives no publication schedule for further reporting or update from Carr.
For now, the confirmed development is the publication of Carr’s personal account and the two health findings described in the available text. Any decisions about genetic testing, heart imaging or treatment require discussion with a qualified clinician who can consider an individual’s health history and circumstances.
Key Questions
What two health notifications does the available report describe?
Carr says a genetic test showed two copies of APOE4, and a later coronary artery calcium scan showed significant calcified plaque in his coronary arteries.
Does having APOE4 mean someone has Alzheimer’s disease?
No. Carr says he learned that APOE4 is a risk factor, not a diagnosis. His personal account does not say that he has Alzheimer’s disease.
What did Carr say the heart scan found?
He reports that the scan showed significant calcified plaque, mostly in the left anterior descending artery. He says his clinician diagnosed atherosclerotic cardiovascular disease and adjusted his cholesterol-related care.
What was the third notification?
The source text supplied here does not describe it. It ends before Carr’s full account is complete, so the third notification and its details remain unknown from this material.
Does Carr’s story show that testing or lifestyle changes prevent Alzheimer’s?
No. It is a first-person report about how Carr responded to health information, not a clinical study demonstrating prevention. Questions about personal testing or care should be discussed with a qualified clinician.
Source: rss
